Diamedica Therapeutics Stock Buy Hold or Sell Recommendation
| DMAC Stock | USD 4.62 0.08 1.70% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding DiaMedica Therapeutics is 'Hold'. Macroaxis provides DiaMedica Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding DMAC positions.
Check out DiaMedica Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide. In addition, we conduct extensive research on individual companies such as DiaMedica and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
DiaMedica |
Execute DiaMedica Therapeutics Buy or Sell Advice
The DiaMedica recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on DiaMedica Therapeutics. Macroaxis does not own or have any residual interests in DiaMedica Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute DiaMedica Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | OK | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
DiaMedica Therapeutics Trading Alerts and Improvement Suggestions
| DiaMedica Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (19.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| DiaMedica Therapeutics currently holds about 38.44 M in cash with (18.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| DiaMedica Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 26.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: DiaMedica Therapeutics Reports Q3 2024 Financial Results - TipRanks |
DiaMedica Therapeutics Returns Distribution Density
The distribution of DiaMedica Therapeutics' historical returns is an attempt to chart the uncertainty of DiaMedica Therapeutics' future price movements. The chart of the probability distribution of DiaMedica Therapeutics daily returns describes the distribution of returns around its average expected value. We use DiaMedica Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of DiaMedica Therapeutics returns is essential to provide solid investment advice for DiaMedica Therapeutics.
| Mean Return | 0.30 | Value At Risk | -3.29 | Potential Upside | 4.94 | Standard Deviation | 3.02 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of DiaMedica Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
DiaMedica Stock Institutional Investors
| Shares | Ronald Blue Trust, Inc. | 2024-09-30 | 44.2 K | Susquehanna International Group, Llp | 2024-06-30 | 43.4 K | Catalyst Financial Partners Llc | 2024-09-30 | 38.5 K | Jefferies Financial Group Inc | 2024-09-30 | 26 K | Citigroup Inc | 2024-09-30 | 22.1 K | Stonebridge Capital Advisors Llc | 2024-09-30 | 17.5 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 17 K | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 15.2 K | Jane Street Group Llc | 2024-06-30 | 15.1 K | Cooperman Leon G | 2024-09-30 | 1.5 M | Vanguard Group Inc | 2024-09-30 | 1 M |
DiaMedica Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (12.9M) | 3.5M | (2.7M) | 21K | (185K) | (175.8K) | |
| Free Cash Flow | (9.1M) | (9.2M) | (12.3M) | (11.6M) | (18.8M) | (17.8M) | |
| Other Non Cash Items | 49K | 52K | 58K | 53K | (1.2M) | (1.1M) | |
| Capital Expenditures | 50K | 2K | 47K | 81K | 24K | 22.8K | |
| Net Income | (10.6M) | (12.3M) | (13.6M) | (13.7M) | (19.4M) | (18.4M) | |
| End Period Cash Flow | 3.9M | 7.4M | 4.7M | 4.7M | 4.5M | 3.5M | |
| Change To Netincome | 1.2M | 1.8M | 1.8M | 1.6M | 1.8M | 1.9M |
DiaMedica Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to DiaMedica Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that DiaMedica Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a DiaMedica stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.28 | |
β | Beta against Dow Jones | 0.06 | |
σ | Overall volatility | 3.04 | |
Ir | Information ratio | 0.05 |
DiaMedica Therapeutics Volatility Alert
DiaMedica Therapeutics currently demonstrates below-average downside deviation. It has Information Ratio of 0.05 and Jensen Alpha of 0.28. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure DiaMedica Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact DiaMedica Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.DiaMedica Therapeutics Fundamentals Vs Peers
Comparing DiaMedica Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze DiaMedica Therapeutics' direct or indirect competition across all of the common fundamentals between DiaMedica Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as DiaMedica Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of DiaMedica Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing DiaMedica Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare DiaMedica Therapeutics to competition |
| Fundamentals | DiaMedica Therapeutics | Peer Average |
| Return On Equity | -0.35 | -0.31 |
| Return On Asset | -0.24 | -0.14 |
| Current Valuation | 151.14 M | 16.62 B |
| Shares Outstanding | 42.76 M | 571.82 M |
| Shares Owned By Insiders | 26.22 % | 10.09 % |
| Shares Owned By Institutions | 31.61 % | 39.21 % |
| Number Of Shares Shorted | 175.55 K | 4.71 M |
| Price To Earning | (3.52) X | 28.72 X |
| Price To Book | 4.19 X | 9.51 X |
| EBITDA | (19.31 M) | 3.9 B |
| Net Income | (19.38 M) | 570.98 M |
| Cash And Equivalents | 38.44 M | 2.7 B |
| Cash Per Share | 1.45 X | 5.01 X |
| Total Debt | 400 K | 5.32 B |
| Current Ratio | 25.50 X | 2.16 X |
| Book Value Per Share | 1.34 X | 1.93 K |
| Cash Flow From Operations | (18.73 M) | 971.22 M |
| Short Ratio | 3.88 X | 4.00 X |
| Earnings Per Share | (0.56) X | 3.12 X |
| Price To Earnings To Growth | (0.07) X | 4.89 X |
| Target Price | 7.0 | |
| Number Of Employees | 18 | 18.84 K |
| Beta | 1.46 | -0.15 |
| Market Capitalization | 200.97 M | 19.03 B |
| Total Asset | 54.16 M | 29.47 B |
| Retained Earnings | (115.56 M) | 9.33 B |
| Working Capital | 50.89 M | 1.48 B |
| Current Asset | 5.24 M | 9.34 B |
| Current Liabilities | 1.05 M | 7.9 B |
| Net Asset | 54.16 M |
Note: Acquisition by Gruis Kirsten L of 160000 shares of DiaMedica Therapeutics at 3.88 subject to Rule 16b-3 [view details]
DiaMedica Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as DiaMedica . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About DiaMedica Therapeutics Buy or Sell Advice
When is the right time to buy or sell DiaMedica Therapeutics? Buying financial instruments such as DiaMedica Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having DiaMedica Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Chemicals Makers Thematic Idea Now
Chemicals Makers
Companies developing chemicals for crops, soil as well as human, and animals. The Chemicals Makers theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Chemicals Makers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out DiaMedica Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.56) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.